11 7.3. Post- Vaccination Prostate Cancer Therapy ....................................................................... 11 8. Efficacy Analysis ................................ .................................................................................. 11 8.1. Analytic Standards ............................................................................................................. 11 8.1.1. Data Cutoff Date ..................................................................................................... 11 8.1.2. One-sided P Values ................................................................................................. 11 8.1.3. Assessing Clinical Site Homogeneity ..................................................................... 12 8.2. Primary Analyses (Survival) .............................................................................................. 12 8.2.1. Imputation of Missing Efficacy Data ...................................................................... 12 8.2.2. Survival Analysis Method ....................................................................................... 13 8.2.3. Survival Graphs ...................................................................................................... 14 8.2.4. Other Analyses of Survival ..................................................................................... 14 8.3. Secondary Endpoint (Alive Without Event [AWE] at Six Months) .................................. 15 8.3.1.